Prolonged Time to Surgery in Patients With Residual Disease After Neoadjuvant Chemoradiotherapy for Esophageal Cancer
Hidde Overtoom(Erasmus MC), Pieter C. van der Sluis(University Medical Center Utrecht), Bas P. L. Wijnhoven(Erasmus MC Cancer Institute), Bo Jan Noordman(Erasmus MC Cancer Institute), Sjoerd M. Lagarde(University of Amsterdam), Ben M. Eyck(Erasmus MC Cancer Institute), Berend J. van der Wilk(Erasmus MC Cancer Institute), J.J.B. van Lanschot(Erasmus MC)
Cited by 8
Related Papers
Ten-Year Outcome of Neoadjuvant Chemoradiotherapy Plus Surgery for Esophageal Cancer: The Randomized Controlled CROSS Trial
|Journal of Clinical Oncology|2021|788
Extended Transthoracic Resection Compared With Limited Transhiatal Resection for Adenocarcinoma of the Mid/Distal Esophagus
|Annals of Surgery|2007|709